DZ Bank Adjusts Price Target on Regeneron Pharmaceuticals
DZ Bank has updated its price target for Regeneron Pharmaceuticals, raising it to $1,067 from $900.
Stocks · News reference
Regeneron Executive Discusses AI in Drug Development
Regeneron's George Yancopoulos shared perspectives on the role of artificial intelligence in laboratory activities and drug development timelines.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Intellia Therapeutics and Regeneron Complete Enrollment in Phase 3 Trial of nex-z
Intellia Therapeutics, in collaboration with Regeneron Pharmaceuticals, has completed enrollment for the Phase 3 MAGNITUDE-2 clinical trial of nex-z for the treatment of ATTRv-PN.
Bank of America Adds Regeneron to 'Value 10' Portfolio
Bank of America Securities has added Regeneron Pharmaceuticals to its 'Value 10' portfolio for November, citing its inclusion in the firm's quantitative model for S&P 500 stocks.
BAYRY Q3 Earnings and Revenues Miss Estimates, Pharma Performs Well
Bayer reported Q3 2026 core EPS of 11 cents, missing estimates of 13 cents, with a 36.7% year-over-year decline. Sales rose 4.1% to $11.57 billion but fell short of the $11.70 billion consensus. The Pharmaceuticals division drove growth with Nubeqa surging 58.3% and Kerendia jumping 64.9%, while Crop Science faced headwinds from weather and regulatory challenges. Bayer raised its 2026 EBITDA guidance, reflecting stronger pharmaceutical profitability.
Wall Street Analysts Update Ratings and Price Targets for Regeneron Pharmaceuticals
Multiple financial institutions updated their investment ratings and price targets for Regeneron Pharmaceuticals, Inc. on November 3, 2026.
Regeneron Announces Management Participation in Upcoming Investor Conferences
Regeneron Pharmaceuticals has scheduled management participation for three upcoming healthcare investor conferences in late 2026.